Literature DB >> 32868324

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.

Thibaut Gelé1,2, Hélène Gouget2, Valérie Furlan3, Pierre-Hadrien Becker4, Anne-Marie Taburet2, Olivier Lambotte2,5,6, Aurélie Barrail-Tran7,2,8.   

Abstract

This study aimed to characterize in vitro dolutegravir (DTG) and bictegravir (BIC) binding. They had a preferential binding to human serum albumin (HSA) with two classes of albumin sites. Human alpha-1-acid glycoprotein (HAAG) binding of DTG and BIC showed an atypical nonlinear binding. The low-affinity site on HSA, the main plasma binding protein, suggests that the high protein binding rate should not impair passive diffusion.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  bictegravir; dolutegravir; human alpha-1-acid glycoprotein; human serum albumin; pharmacokinetics; protein binding

Year:  2020        PMID： 32868324      PMCID： PMC7577134          DOI： 10.1128/AAC.00895-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  The pH dependency of the binding of drugs to plasma proteins in man.

Authors:  Peter H Hinderling; Dieter Hartmann
Journal:  Ther Drug Monit       Date:  2005-02       Impact factor: 3.681

Review 2.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

3.  Intrathecal administration of high-dose morphine solutions decreases the pH of cerebrospinal fluid.

Authors:  Michel F M Wagemans; Eke N Bakker; Wouter W A Zuurmond; Emiel M Spoelder; Arie C Van Loenen; Jaap J De Lange
Journal:  Pain       Date:  1995-04       Impact factor: 6.961

4.  Determination of atypical nonlinear plasma−protein-binding behavior of tigecycline using an in vitro microdialysis technique.

Authors:  Jatinder Kaur Mukker; Ravishankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2014-01-24       Impact factor: 3.534

5.  The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.

Authors:  Lee Moss; David Wagner; Eri Kanaoka; Katie Olson; Yun Lan Yueh; Gary D Bowers
Journal:  Xenobiotica       Date:  2014-07-18       Impact factor: 1.908

6.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

7.  Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.

Authors:  Benjamin N Greener; Kristine B Patterson; Heather M A Prince; Craig S Sykes; Jessica L Adams; Julie B Dumond; Nicholas J Shaheen; Ryan D Madanick; Evan S Dellon; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

Review 8.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.

Authors:  Anthony T Podany; Kimberly K Scarsi; Courtney V Fletcher
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

9.  Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.

Authors:  Joel E Gallant; Melanie Thompson; Edwin DeJesus; Gene W Voskuhl; Xuelian Wei; Heather Zhang; Kirsten White; Andrew Cheng; Erin Quirk; Hal Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

10.  Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment.

Authors:  Thibaut Gelé; Valérie Furlan; Anne-Marie Taburet; Coralie Pallier; Pierre-Hadrien Becker; Cécile Goujard; Jacques Gasnault; Aurélie Barrail-Tran; Antoine Chéret
Journal:  Open Forum Infect Dis       Date:  2019-06-03       Impact factor: 3.835
View more
  1 in total

1.  Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.

Authors:  Lauren Kirkwood-Johnson; Nana Katayama; Yusuke Marikawa
Journal:  Toxicol Sci       Date:  2021-11-24       Impact factor: 4.849
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.